Victor Schut has been appointed as the new Chief Executive Officer (CEO) of AGILeBiotics and co-founder Dr. Andreas A. Bastian has now taken on the role of Chief Operating Officer (COO). Currently raising Series A investment, the appointments come in line with the company’s plans and development strategy.
Victor joined the AGILeBiotics team in June 2019 as Chief Business Officer (CBO) bringing the required experience and strengthening the team in preparation for the next phase of the company. Closing the current financing round will enable the company to bring its lead compound, Toframicin, to the clinic. Toframicin is the next-generation antibiotic for the treatment of multidrug-resistant infections.
Read more on the AGILeBiotics website.